<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104180</url>
  </required_header>
  <id_info>
    <org_study_id>LINE4001</org_study_id>
    <secondary_id>2013-A01285-40</secondary_id>
    <nct_id>NCT02104180</nct_id>
  </id_info>
  <brief_title>Evaluation of Pain Associated With the Removal of Wound Dressing During Care of Venous Leg Ulcer. Comparison of the Efficacy and Safety of Two Dressings Urgotul and TulleGras</brief_title>
  <official_title>Evaluation of the Non-inferiority of TulleGras M.S.® Versus Urgotul® in Pain Associated With Removal of Wound Dressing During Care of Venous Leg Ulcer. An Open-label, Multicenter, Randomized, Controlled, Crossover Study With Blinded Reading of Healing Criteria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CEN Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the non-inferiority of TulleGras M.S.® versus Urgotul® in pain associated with
      removal of wound dressing during care of venous leg ulcer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity at removal of the primary dressing, evaluated by the subject just after removal</measure>
    <time_frame>at the time of dressing removal</time_frame>
    <description>pain at dressing removal patient self-assessment diary during the Crossover period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of subjects with healing of venous leg ulcer greater than or equal to 40%</measure>
    <time_frame>At the 8th week of the Follow up Period Day 60 / Visit 5</time_frame>
    <description>planimetry technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Means of variations in the ulcer area</measure>
    <time_frame>between Day 0 (Visit 1) and Day 88 (Visit 6).</time_frame>
    <description>planimetry technique + photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequencies of subjects with complete healing of venous leg ulcer</measure>
    <time_frame>at each visit (D2, D4, D32, D60, D88)</time_frame>
    <description>Call to the patients 4 weeks after complete healing (confirm lack of relapse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the dressings</measure>
    <time_frame>at each visit (D1 to D88)</time_frame>
    <description>number of patients with incidents as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>TulleGras M.S.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Urgotul</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Urgotul</intervention_name>
    <description>sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline</description>
    <arm_group_label>Urgotul</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TulleGras M.S.</intervention_name>
    <description>Sterile dressing that consists of viscose tissue coated with mineral vaseline</description>
    <arm_group_label>TulleGras M.S.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject informed of the objectives, purpose, details and constraints of the study and
             who has given his/her written informed consent.

          -  Male or female subject.

          -  Subject at least 45 years of age.

          -  Subject presenting with an open venous leg ulcer.

          -  Age of venous leg ulcer between 1 month and 12 months inclusive at the Inclusion Visit
             (Visit 1).

          -  Venous leg ulcer whose area is between 4 cm2 and 50 cm2 inclusive at the Inclusion
             Visit (Visit 1).

          -  Venous leg ulcer in the granulation phase over 50% of its area at the Inclusion Visit
             (Visit 1);

        Exclusion Criteria:

        Related to the disease studied:

          -  Venous leg ulcer for which surgery is indicated or for which a surgical procedure is
             planned within twelve weeks of inclusion in the study (Visit 1).

          -  Venous leg ulcer at start of cleaning phase;

          -  Fibrinous and dry ulcer (non exudative wound) or on the contrary highly exudative
             and/or hemorrhagic.

          -  Venous leg ulcer with signs of critical colonization or clinically infected.

          -  Cancerous venous leg ulcer.

        Related to the subject:

          -  Subject presenting with a serious systemic disease, which may lead to premature
             termination of the study before the end of the twelve weeks of treatment of the Follow
             up Period.

          -  Subject with a medical history or a significant disease revealed by history which can
             limit his/her participation or prevent the subject from completing the study.

          -  Subject presenting with a progressive neoplasm, treated with radiotherapy or
             chemotherapy or immunosuppressant therapy or high-dose corticosteroids.

          -  Subject who underwent surgery directly related to his/her venous disease during the
             two months prior to Inclusion Visit (Visit 1).

          -  Subject with poorly controlled diabetes.

          -  Subject who presented with a deep venous thrombosis during the 3 months prior to
             Inclusion Visit (Visit 1).

          -  Subject confined to bed.

          -  Woman of child-bearing potential (NOT postmenopausal for at least 24 months or NOT
             surgically sterilized (tubal ligation) or NOT hysterectomized) who is NOT routinely
             using adequate and efficient hormonal contraception or barrier method (intrauterine
             device, diaphragm, combination of condom and spermicide) prior to and during the
             trial.

          -  Subject whose ankle has a circumference, measured at the Inclusion Visit (Visit 1),
             greater than 32 cm (&gt; 32 cm).

          -  Subject presenting with symptomatic or asymptomatic peripheral arterial disease,
             particularly with a distal systolic pressure index, measured at the Inclusion Visit
             (Visit 1), ≤0.8 or ≥1.3.

          -  Subject with a history of allergic reaction(s) to one of the different components of
             the dressings or with a contra-indication to the use of one of these dressings.

          -  Known history of alcohol abuse or drug abuse.

          -  Subject linguistically or psychologically unable to understand the information given
             and to provide informed consent.

          -  Subject participating in or who participated in another clinical study within 4 weeks
             prior to the Inclusion Visit (Visit 1).

          -  Subject not covered by or not a beneficiary of the Social Security system.

          -  Subject deprived of his freedom as the result of a legal or administrative decision or
             subject to legal guardianship.

          -  Any other reason, in the investigator's opinion, that prohibits the inclusion of the
             subject into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Lesaunier, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility ID ORG-001183</name>
      <address>
        <city>Angoulème</city>
        <zip>16000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000857</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000853</name>
      <address>
        <city>Asnieres</city>
        <zip>92600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000981</name>
      <address>
        <city>Beaune</city>
        <zip>21200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000844</name>
      <address>
        <city>Boulogne sur Mer</city>
        <zip>62200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000869</name>
      <address>
        <city>Bourgoin Jallieu</city>
        <zip>38300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001215</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001181</name>
      <address>
        <city>Figeac</city>
        <zip>46100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001081</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000850</name>
      <address>
        <city>Hazebrouck</city>
        <zip>59190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000855</name>
      <address>
        <city>Lattes</city>
        <zip>34970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000859</name>
      <address>
        <city>Laxou</city>
        <zip>54520</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000830</name>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ORG-001362</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001182</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000836</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ORG-001361</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000831</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000832</name>
      <address>
        <city>Paris</city>
        <zip>75116</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000856</name>
      <address>
        <city>Pezenas</city>
        <zip>34120</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001082</name>
      <address>
        <city>Saint Aubin Sur Scie</city>
        <zip>76550</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000865</name>
      <address>
        <city>Saint Maur</city>
        <zip>94100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000845</name>
      <address>
        <city>Tarare</city>
        <zip>69170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001216</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001083</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000862</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000835</name>
      <address>
        <city>Vincennes</city>
        <zip>94300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-inferiority</keyword>
  <keyword>randomized</keyword>
  <keyword>TulleGras</keyword>
  <keyword>Urgotul</keyword>
  <keyword>pain</keyword>
  <keyword>venous leg ulcer</keyword>
  <keyword>healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 11, 2017</submitted>
    <returned>June 23, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

